Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:09 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies
NCT00649584 · Seagen Inc. · PHASE1 · terminated · last registry update 2014-12-18 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sponsor decision not to enroll cohorts of combined SGN-35 and gemcitabine therapy.” | – | Registry record, Seagen Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TUBB4B within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2015-10-05Phase 3 first posted: National Cancer Institute (NCI), Cyclophosphamide + Dactinomycin (NCT02567435)
- 2015-07-01Phase 3 first posted: Hoffmann-La Roche, Atezolizumab + Cisplatin (NCT02486718)
- 2015-05-27Phase 3 first posted: Alicia Lenzen, Carboplatin and Vincristine + Carboplatin (NCT02455245)
- 2015-03-19Results posted on the registry: Genentech, Inc., obinutuzumab + cyclophosphamide (NCT01414855)
- 2014-12-03Phase 3 first posted: National Cancer Institute (NCI), Cyclophosphamide + Doxorubicin (NCT02306161)
- 2014-07-31Phase 3 first posted: North American Consortium for Histiocytosis, Prednisone + Vinblastine (NCT02205762)
- 2014-06-18Phase 3 first posted: National Cancer Institute (NCI), Bleomycin Sulfate + Brentuximab Vedotin (NCT02166463)
- 2014-04-14Phase 3 first posted: National Cancer Institute (NCI), Bortezomib + Cyclophosphamide (NCT02112916)
- 2014-04-02Phase 3 first posted: National Cancer Institute (NCI), Asparaginase + Blinatumomab (NCT02101853)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision